Dose-related paresthesias with venlafaxine

Area of Science:

• Neuroscience
• Pharmacology
• Psychiatry

Background:

• Venlafaxine is a widely prescribed serotonin norepinephrine reuptake inhibitor (SNRI).
• It is indicated for treating mood, anxiety, and pain disorders.
• Adverse drug reactions require careful monitoring and reporting.

Observation:

• A case study involving a young male patient with major depressive disorder treated with venlafaxine XR.
• Paresthesias, including tingling, numbness, and itching in the upper extremities, emerged upon dose increase to 150 mg/day.
• Symptoms recurred upon dose re-escalation and resolved with dose reduction.

Findings:

• The patient experienced dose-related paresthesias attributed to venlafaxine.
• The Naranjo scale indicated a probable adverse drug reaction (score of 5).
• Published evidence suggests paresthesias are associated with antidepressant use.

Implications:

• Clinicians should be vigilant for paresthesias during venlafaxine treatment, particularly at doses of 150 mg/day or higher.
• Patients with pain disorders on venlafaxine require close monitoring for symptom exacerbation.
• Dose adjustments may be necessary to manage venlafaxine-induced paresthesias.